Advaxis Zips Listeria/Opdivo Combo Straight To Registrational Cervical Cancer Trial

31 May 2017

• By Emily Hayes

Potentially registrational trial of ADXS-DUAL Listeria-based vaccine with Bristol's PD-1 inhibitor Opdivo in recurrent metastatic cervical cancer will complement Advaxis's adjuvant study of earlier-generation candidate axalimogene filolisbac.

Advaxis Zips Listeria/Opdivo Combo Straight To Registrational Cervical Cancer Trial

More from R&D

More from Scrip